Key Takeaways
Improvements in upstream productivity can shift biomanufacturing bottlenecks into downstream purification, particularly when chromatography capacity cannot accommodate increased product mass.
Higher-titer and higher-cell-density processes can also increase solids and process-related impurity burdens, placing additional pressure on harvest clarification and filtration.
Downstream capacity depends on more than chromatography throughput; intermediate pool volumes, tankage, virus filtration, and buffer management can all become limiting.
Technologies, including multi-column chromatography, SPTFF, convective chromatography, and connected processing, can relieve specific downstream constraints, but improvements at individual steps do not necessarily translate directly into greater facility throughput.
As downstream processes become more intensified and interconnected, scheduling, automation, and coordinated process control play a larger role in translating higher upstream productivity into manufacturing output.
Downstream Processing Is Becoming the Capacity Bottleneck
Upstream bioprocessing has become increasingly productive, but greater output from the bioreactor does not automatically translate into greater manufacturing throughput. As more product mass reaches purification, downstream operations must absorb the additional load within the constraints of chromatography capacity, filtration area, intermediate storage, buffer infrastructure, equipment availability, and processing time. Studies of continuous and intensified monoclonal antibody (mAb) manufacturing have shown that increasing upstream production can shift limiting operations downstream, including into multi-column chromatography and other purification steps.1–3
The implications extend well beyond the capacity of an individual chromatography column. Higher-productivity upstream processes can also be accompanied by higher-cell-density harvests with greater solids and process-related impurity burdens, increasing the challenge presented to clarification before capture even begins.4,5 Greater product mass can enlarge intermediate pools and increase tank requirements, while more intensive downstream operation can place additional demands on virus filtration, buffer preparation and delivery, scheduling, automation, and process coordination.
The result is a capacity challenge that spans the connected manufacturing train. Translating upstream productivity into finished-product throughput depends on how effectively the downstream process can handle the resulting mass, volume, and operating cadence.3,6
Upstream Productivity Is Moving the Constraint
Higher upstream productivity increases the amount of product that purification operations must process during a manufacturing campaign, potentially shifting the principal capacity constraint away from the bioreactor and into the downstream train. In integrated process models, increasing upstream production has caused downstream multi-column chromatography operations to become limiting steps.1–3
That distinction matters because upstream production capacity and facility throughput are not interchangeable. The downstream process must still capture the product, remove impurities, complete viral clearance operations, polish the molecule, handle intermediate pools, and move material into subsequent processing. A continuous downstream control strategy developed to accommodate variable upstream titers required coordinated adjustment across capture chromatography, viral inactivation, depth filtration, polishing chromatography, and formulation.
The manufacturing question shifts from how much material upstream can generate to how much of that material the complete process can move through the facility within the required campaign window.
Protein A Capture Feels the Pressure First
For mAb processes, protein A capture represents one of the most visible places where greater upstream output meets downstream constraints. The operation is relatively low in productivity and high in cost, and greater product mass increases the load that must move through the capture step.7
Conventional packed-bed chromatography also imposes transport limitations. Mass transfer into porous resin particles depends substantially on diffusion, which can require longer residence times and constrain the rate at which a column can process material. As upstream productivity increases, accommodating the resulting load may require changes in column utilization, cycling strategy, or the overall capture configuration.2
Multi-column chromatography offers one route to greater utilization of available stationary-phase capacity. By coordinating loading and cycling across multiple columns, these configurations can use binding capacity differently from conventional single-column batch operation and increase capture throughput. Convective formats, including membrane and fiber chromatography, provide another approach because material transport is less dependent on diffusion into porous beads.2,8
Reducing the volume presented to capture can address the same pressure from another direction. Single-pass tangential flow filtration (SPTFF) positioned ahead of protein A has been used to concentrate clarified cell culture fluid before capture. In one demonstrated process, inline concentration increased protein A productivity relative to processing unconcentrated feed, illustrating how reducing volumetric load can help capture accommodate more productive upstream operations.7
These approaches relieve different limitations within capture, but none operates independently of the surrounding process.
Clarification Faces a More Demanding Feed
The pressure created by upstream intensification can appear before the first chromatography column. Higher-titer mammalian cell culture has been associated with higher cell densities and greater quantities of process-related impurities, including DNA and host cell proteins. High-cell-density cultures can also increase cellular debris, solids, and submicron material entering harvest.4,5
Clarification must thus handle more than an increase in product quantity. The characteristics of the feed itself can become more demanding, with implications for depth-filtration capacity and filter-area requirements. In one study, pretreatment of high-cell-density material substantially reduced the depth-filter area required for clarification, demonstrating how harvest conditions and pretreatment strategy can materially alter downstream filtration demand.5 The magnitude of that improvement was specific to the process evaluated, but the broader capacity implication is clear: the burden on downstream equipment is influenced by both the quantity and characteristics of the material delivered from upstream.
Clarification choices can also affect what happens later. Harvest-stage operation has been shown to influence subsequent protein A performance, and work combining clarification, SPTFF, and capture has demonstrated that differences in clarification strategy alter the material presented to the concentration and capture operations.4,7
That linkage makes clarification part of the broader downstream capacity problem rather than a discrete preliminary step.
Intermediate Pools Can Become Facility Constraints
Not all downstream bottlenecks are located inside separation equipment. As product mass increases, the volumes and infrastructure required between purification steps can become limiting as well. Higher titers can create requirements for greater chromatography capacity and larger intermediate product-pool holding tanks, and intermediate pools can become significant constraints when an existing facility was designed around lower product mass.9
A downstream suite may consequently have suitable chromatography technology but insufficient tankage to accommodate the resulting pools efficiently. Larger intermediate volumes can increase tankage requirements and create additional facility-fit constraints.
SPTFF has been investigated specifically as a way to address this type of constraint. By concentrating process streams between operations, the technology can reduce intermediate volumes and the burden placed on pool tanks. Early work on SPTFF for therapeutic antibody processing evaluated reductions in intermediate volume as a strategy for debottlenecking facilities where tank size limited downstream capacity.10
More recent facility-level modeling reinforces the importance of looking beyond individual equipment specifications. Analyses of downstream intensification in existing biopharmaceutical facilities have evaluated feed titer, protein A capture, polishing, viral filtration, and scheduling together rather than treating each operation independently. The benefit of a particular intensification strategy depends on the broader production scenario and how the complete facility operates.6
For contract development and manufacturing organizations (CDMOs), this distinction is particularly relevant. The ability to accommodate an upstream campaign does not by itself establish that the facility can move the resulting mass through purification at the required pace. Downstream fit depends on the relationship among the process, available equipment, supporting infrastructure, and manufacturing schedule.
Buffer Management Enters the Capacity Equation
Buffers illustrate how supporting operations can become part of the bottleneck as downstream processing intensifies. Chromatography and filtration depend on reliable preparation and delivery of process solutions, and prolonged or continuous downstream operation can require multiple buffers to remain available over extended processing periods. Buffer management has consequently been identified as a potential bottleneck in continuous downstream bioprocessing.
In a published case, an automated buffer-management demonstration prepared and supplied nine buffers during a 10-day continuous downstream process.11 The scale and configuration were specific to that study, but the example highlights the coordination required to keep an intensified process supplied without allowing buffer preparation or availability to interrupt primary purification operations.
Manufacturing-level modeling has likewise characterized buffer management as a recurring production constraint and evaluated inline preparation as an alternative to conventional preparation and storage. The benefits of inline preparation depend on operating decisions, such as stock-solution concentration, shift patterns, process requirements, and whether preparation can serve multiple batches.12
Conventional buffer preparation also interacts with production scheduling. As downstream operations become faster or more continuous, solution preparation and delivery must operate at a cadence that supports them.
Solving One Bottleneck Can Reveal the Next
Downstream intensification becomes more complex when changes made to relieve one constraint alter the material or timing presented to another operation.
Feed concentration provides a clear example. SPTFF can reduce the volume entering protein A capture and improve capture productivity, but concentrating material also changes the conditions seen by later steps. Virus-filtration studies designed around intensified and continuous mAb processing have demonstrated that protein concentration and filtration duration can influence filtration performance and that conventional approaches to viral-clearance evaluation may need to be adapted to these operating conditions.7,13
The same principle appears earlier in the process. Clarification strategy affects the characteristics of the material entering concentration and capture, demonstrating that decisions at harvest can shape later downstream performance.
Integrated-process modeling makes the consequence particularly clear. When upstream production was increased to determine where a continuous process would become constrained, downstream multi-column chromatography operations emerged as bottlenecks. Which operation became limiting depended on the capacity utilization of the individual steps within the integrated train.
Facility-level modeling reaches a complementary conclusion. Intensifying individual downstream operations can improve particular economic, environmental, or operational metrics without producing an equivalent increase in overall facility throughput. In the scenarios evaluated, scheduling could have a greater impact on overall productivity than reductions in the processing time of individual unit operations.
The optimization target is the throughput of the complete manufacturing train. Increasing the productivity of one operation matters only if the surrounding process can use that additional capacity.
Connected Processing Can Reduce Interstep Constraints
One way to address constraints between operations is to reduce the number or size of intermediate pools and the time material spends waiting between steps. Pool-less processing has been demonstrated as a means of connecting polishing operations, reducing or eliminating intermediate holding requirements and shortening overall processing time. This approach directly addresses facility-fit problems that emerge when higher product mass exceeds the intermediate storage capacity available in an existing downstream suite.9
SPTFF can contribute to the same objective by reducing process-stream volumes before capture or between downstream steps. Rather than expanding every tank or chromatography asset in proportion to upstream output, concentration can decrease the volume that subsequent operations need to accommodate.
Alternative chromatographic formats can further compress parts of the purification train. Fiber-enabled process intensification has been demonstrated in a process with fewer purification stages than a legacy comparison and with improvements in yield, buffer consumption, and step productivity.8 Those results reflect one specific process configuration, but they illustrate how downstream intensification can change the number of steps, the material required to operate them, and the capacity consumed by the overall sequence.
Facility modeling cautions against assuming that faster or more intensified operations automatically maximize facility output. Higher overall throughput may require a combination of downstream intensification and changes in production scheduling.
Connected processing is most valuable when it reduces constraints that matter at the process level, including large intermediate pools, processing time, or scheduling gaps that prevent faster unit operations from translating into faster overall production.
Automation and Coordination Support Higher Throughput
As downstream operations become more closely connected, changes in feed titer increasingly require coordinated adjustments across the processing train. Continuous downstream systems have demonstrated the use of real-time titer information to adjust capture and polishing configurations as upstream output changes. More recent integrated downstream work has demonstrated autonomous operation in response to deliberately introduced disturbances, including increased harvest titer.1,14
These approaches illustrate a role for automation that is directly tied to capacity. Coordinated control can help downstream operations remain aligned as the quantity or characteristics of incoming material change.
Scheduling belongs in this discussion as well. Modeling of existing facilities shows that production cadence can strongly influence the overall productivity achieved from intensified downstream operations. Faster equipment cannot deliver its full capacity benefit if campaigns, holds, or shared resources prevent that equipment from being used effectively.
Physical intensification and operational coordination increasingly need to advance together. Chromatography, filtration, buffers, transfers, and supporting operations must function at compatible rates if the downstream process is to absorb greater upstream output.
Available Capacity Requires an End-to-End View
The shift in bottlenecks has practical implications for how sponsors and manufacturing partners evaluate capacity. Bioreactor volume remains important, but it cannot by itself describe the amount of product a facility can manufacture within a given period.
Effective downstream capacity depends on clarification capability, capture and polishing throughput, filtration requirements, intermediate pool volumes, available tankage, buffer preparation and delivery, equipment occupancy, transfer and hold requirements, and the schedule that connects these resources. Studies of high-titer and intensified processing show that limitations can emerge across this broader downstream system.
The resulting constraints may not be obvious when capacity is assessed one asset at a time. A facility may have available bioreactor volume but insufficient downstream tankage. A chromatography operation may have sufficient theoretical binding capacity but require changes in cycling, configuration, or scheduling to handle the mass generated upstream. A faster individual operation may provide limited overall benefit if another unit operation or production scheduling remains limiting.
Virus filtration and buffer management add further examples of how downstream constraints can emerge outside chromatography itself. Intensified operating conditions can change the demands placed on virus filtration, while buffer availability can become a production limitation in prolonged or continuous downstream processing.
These constraints place greater value on end-to-end process understanding during facility selection, technology transfer, and capacity planning. The relevant manufacturing question is not only how much material the upstream process can generate or how large the available bioreactors are. It is how much product the complete process can move through the facility at the required cadence using the downstream equipment and supporting infrastructure actually available.
Upstream productivity has raised the bar for the rest of the process. Extracting its full value increasingly depends on designing the downstream train as a connected manufacturing system whose chromatography, filtration, buffers, pools, controls, and schedule can keep pace with upstream output.
References
1. Thakur, Garima, Vikrant Bansode, and Anurag S Rathore. “Continuous manufacturing of monoclonal antibodies: Automated downstream control strategy for dynamic handling of titer variations.” Journal of Chromatography A. 1682: 463496 (2022).
2. Schmitz, Fabian, et al. “Continuous multi-column capture of monoclonal antibodies with convective diffusive membrane adsorbers.” Biotechnology and Bioengineering. 121: 1859–1875 (2024).
3. Ding, Chaoying, et al. “Process design of a fully integrated continuous biopharmaceutical process using economic and ecological impact assessment.” Biotechnology and Bioengineering. 119: 3567–3583 (2022).
4. Parau, Maria, James Pullen, and Daniel G Bracewell. “Depth filter material process interaction in the harvest of mammalian cells.” Biotechnology Progress. 39: e3329 (2023).
5. Hadpe, Sandeep R, et al. “Pretreatments for enhancing clarification efficiency of depth filtration during production of monoclonal antibody therapeutics.” Biotechnology Progress. 36: e2996 (2020).
6. Romero, Juan J, et al. “Modeling and techno-economic analysis of downstream manufacturing process intensification strategies for existing biopharmaceutical facilities.” Journal of Chromatography A. 1737: 465431 (2024).
7. Rahane, Santosh B, et al. “Concentration of clarified pool by single-pass tangential flow filtration to improve productivity of protein A capture step: Impact of clarification strategies.” Biotechnology and Bioengineering. 121: 1090–1101 (2024).
8. Anderson, Sean M, et al. “Fiber chromatographic enabled process intensification increases monoclonal antibody product yield.” Biotechnology and Bioengineering. 121: 757–770 (2024).
9. Zhang, Jennifer, et al. “Pool-less processing to streamline downstream purification of monoclonal antibodies.” Engineering in Life Sciences. 17: 117–124 (2017).
10. Dizon-Maspat, Jemelle, et al. “Single pass tangential flow filtration to debottleneck downstream processing for therapeutic antibody production.” Biotechnology and Bioengineering. 109: 962–970 (2012).
11. Isaksson, Madelène, et al. “An automated buffer management system for small-scale continuous downstream bioprocessing.” Journal of Chromatography A. 1695: 463942 (2023).
12. Gibson, Kevin, Jorge C Oliveira, and Denis Ring. “Optimisation of biopharmaceutical buffer management to maximise the benefits of inline preparation systems.” Results in Engineering. 25: 104080 (2025).
13. Bohonak, David M, et al. “Adapting virus filtration to enable intensified and continuous monoclonal antibody processing.” Biotechnology Progress. 37: e3088 (2021).
14. Isaksson, Madelène, et al. “Autonomous operation and quality monitoring of a continuous antibody downstream process.” Journal of Chromatography A. 1757: 466157 (2025).
